Literature DB >> 19107483

Cardiac involvement in sickle beta-thalassemia.

Athanasios Aessopos1, Dimitrios Farmakis, Christos Trompoukis, Maria Tsironi, Ioannis Moyssakis, Panagiotis Tsaftarides, Markisia Karagiorga.   

Abstract

Cardiovascular involvement is a leading cause of mortality and morbidity in patients with inherited hemoglobinopathies, but it has not been adequately assessed in sickle beta-thalassemia. We evaluated 115 sickle beta-thalassemia patients, aged 34 +/- 14 years, along with 50 healthy controls, by resting echocardiography. Patients with systolic left ventricular (LV) dysfunction or severe pulmonary hypertension (PHT) also underwent left and right cardiac catheterization and cardiac magnetic resonance imaging (CMR). Left and right chamber dimensions, LV mass, and cardiac index were significantly higher in patients compared to controls (p < 0.001 in most cases). Three patients (2.9%) had reduced LV ejection fraction (<55%); mean LV ejection fraction was significantly lower in patients (p < 0.001). Left and right ventricular systolic tissue Doppler indices and LV diastolic tissue Doppler indices were also impaired in patients. All three patients with systolic LV dysfunction had normal coronary arteries and mild myocardial iron load (CMR T2* values, 18-25 ms). Systolic pulmonary artery pressure was significantly higher in patients compared to controls (p = 0.002); PHT was present in 28 patients (27%), while severe PHT in three (2.9%). In three patients with severe PHT, only one had impaired LV ejection fraction and increased pulmonary wedge pressure. Overall, three patients (2.9%) had a history of heart failure, two with systolic LV dysfunction, and one with severe PHT. Cardiac involvement in sickle beta-thalassemia concerns biventricular dilatation and dysfunction along with PHT, leading to congestive heart failure.

Entities:  

Mesh:

Year:  2008        PMID: 19107483     DOI: 10.1007/s00277-008-0661-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  5 in total

1.  Hemodynamic characteristics and predictors of pulmonary hypertension in patients with sickle cell disease.

Authors:  Melissa C Caughey; Alan L Hinderliter; Susan K Jones; Sanjeev P Shah; Kenneth I Ataga
Journal:  Am J Cardiol       Date:  2012-02-15       Impact factor: 2.778

Review 2.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

3.  Tissue Doppler echocardiographic findings of left ventricle in children with sickle-cell anemia.

Authors:  Mehdi Ghaderian; Bijan Keikhaei; Morteza Heidari; Zahra Salehi; Reza Azizi Malamiri
Journal:  J Tehran Heart Cent       Date:  2012-08-31

4.  Comparison of right and left side heart functions in patients with thalassemia major, patients with thalassemia intermedia, and control group.

Authors:  Noormohammad Noori; Mehdi Mohamadi; Kambiz Keshavarz; Seyed Mostafa Alavi; Maziar Mahjoubifard; Yalda Mirmesdagh
Journal:  J Tehran Heart Cent       Date:  2013-01-08

5.  Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension associated with hemolytic anemia.

Authors:  Sarfraz Saleemi
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.